Market Tracker

05/28 5:30am ET

Athersys Inc (NASDAQ:ATHX)

2.47
Delayed Data
As of May 25
 +0.02 / +0.82%
Today’s Change
1.29
Today|||52-Week Range
2.63
+36.46%
Year-to-Date
BioMarin's Palynziq Gets FDA Approval for Phenylketonuria
May 25 / Zacks.com - Paid Partner Content
Moving Average Crossover Alert: Athersys, Inc. (ATHX)
May 22 / Zacks.com - Paid Partner Content
INSYS Gets Negative FDA Recommendation for Pain Candidate
May 23 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close2.45
Today’s open2.46
Day’s range2.42 - 2.49
Volume421,522
Average volume (3 months)632,998
Market cap$304.9M
Data as of 4:00pm ET, 05/25/2018

Growth & Valuation

Earnings growth (last year)-61.11%
Earnings growth (this year)+20.69%
Earnings growth (next 5 years)+1.00%
Revenue growth (last year)-78.62%
P/E ratioNM
Price/Sales54.70
Price/Book11.54

Competitors

 Today’s
change
Today’s
% change
KURAKura Oncology Inc-0.15-0.87%
OBSVObseva SA-0.06-0.46%
NYMXNymox Pharmaceutical...-0.07-1.88%
MGENMiragen Therapeutics...+0.11+1.60%
Data as of 4:00pm ET, 05/25/2018

Financials

Next reporting dateAugust 8, 2018
EPS forecast (this quarter)$0.00
Annual revenue (last year)$3.7M
Annual profit (last year)-$32.2M
Net profit margin-869.50%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Gil van Bokkelen
President, Chief Operating Officer &
Secretary
William B. J. Lehmann
Corporate headquarters
Cleveland, Ohio

Forecasts